Tenet Healthcare Corporation (THC)
Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat
THC's Q3 profit beats estimates on higher revenues and strong segment growth, but rising costs drag shares lower.
Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Tenet Healthcare (THC) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Tenet Healthcare (THC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tenet Healthcare Corporation (THC) Q3 2025 Earnings Call Transcript
Tenet Healthcare Corporation (NYSE:THC ) Q3 2025 Earnings Call October 28, 2025 10:30 AM EDT Company Participants William McDowell - Vice President of Investor Relations Saumya Sutaria - Chairman & CEO Sun Park - Executive VP & CFO Conference Call Participants Kevin Fischbeck - BofA Securities, Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Craig Hettenbach - Morgan Stanley, Research Division Jason Cassorla - Guggenheim Securities, LLC, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Ryan Langston - TD Cowen, Research Division Justin Lake - Wolfe Research, LLC Brian Tanquilut - Jefferies LLC, Research Division Albert Rice - UBS Investment Bank, Research Division Joshua Raskin - Nephron Research LLC Benjamin Mayo - Leerink Partners LLC, Research Division Thomas Walsh - Barclays Bank PLC, Research Division Presentation Operator Good morning, welcome to Tenet Healthcare's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] I'll now turn the call over to your host, Mr.
Tenet (THC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Tenet (THC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings?
THC's third-quarter results may show profit growth despite lower patient days and mixed hospital trends.
Tenet Healthcare: USPI Momentum Expected To Sustain Q3 Earnings, Why I Choose To Buy
Tenet Healthcare is rated BUY, driven by its strategic shift to high-margin outpatient care and strong growth in its USPI division. THC benefits from policy tailwinds, expanding outpatient-eligible procedures, and attractive valuation with a forward EV/EBITDA of 7.33, well below industry peers. Key risks include heavy reliance on Medicare/Medicaid, ongoing litigation at St. Vincent Hospital, and operational leverage, though these appear over-reflected in the current valuation.
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Tenet Healthcare (THC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
